Evidence map›Paper›PMID 37628903›Full record

ArticleInternational journal of molecular sciences2023

Genomic Evolution and Transcriptional Changes in the Evolution of Prostate Cancer into Neuroendocrine and Ductal Carcinoma Types.

Srinivasa R Rao, Andrew Protheroe, Lucia Cerundolo, David Maldonado-Perez, Lisa Browning, Alastair D Lamb, Richard J Bryant, Ian G Mills, Dan J Woodcock, Freddie C Hamdy and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Srinivasa R RaoNuffield Department of Surgical Sciences, University of Oxford, Oxford OX3 9DU, UK.ORCID 0000-0003-1889-6530
Andrew ProtheroeNuffield Department of Surgical Sciences, University of Oxford, Oxford OX3 9DU, UK.ORCID 0000-0001-9413-0575
Lucia CerundoloNuffield Department of Surgical Sciences, University of Oxford, Oxford OX3 9DU, UK.
David Maldonado-PerezOxford Centre for Histopathology Research, University of Oxford, Oxford OX3 9DU, UK.
Lisa BrowningNuffield Department of Surgical Sciences, University of Oxford, Oxford OX3 9DU, UK.ORCID 0000-0003-4254-333X
Alastair D LambNuffield Department of Surgical Sciences, University of Oxford, Oxford OX3 9DU, UK.
Richard J BryantNuffield Department of Surgical Sciences, University of Oxford, Oxford OX3 9DU, UK.ORCID 0000-0002-8330-9251
Ian G MillsNuffield Department of Surgical Sciences, University of Oxford, Oxford OX3 9DU, UK.ORCID 0000-0001-5347-5083
Dan J WoodcockNuffield Department of Surgical Sciences, University of Oxford, Oxford OX3 9DU, UK.
Freddie C HamdyNuffield Department of Surgical Sciences, University of Oxford, Oxford OX3 9DU, UK.
Ian P M TomlinsonDepartment of Oncology, University of Oxford, Oxford OX3 7DQ, UK.
Clare VerrillNuffield Department of Surgical Sciences, University of Oxford, Oxford OX3 9DU, UK.
University of Oxford · GB

Funding

Cancer Research UK 18444Cancer Research UK 25812
6 · The paper itself

Abstract

Prostate cancer is typically of acinar adenocarcinoma type but can occasionally present as neuroendocrine and/or ductal type carcinoma. These are associated with clinically aggressive disease, and the former often arises on a background of androgen deprivation therapy, although it can also arise de novo. Two prostate cancer cases were sequenced by exome capture from archival tissue. Case 1 was de novo small cell neuroendocrine carcinoma and ductal adenocarcinoma with three longitudinal samples over 5 years. Case 2 was a single time point after the development of treatment-related neuroendocrine prostate carcinoma. Case 1 showed whole genome doubling in all samples and focal amplification of AR in all samples except the first time point. Phylogenetic analysis revealed a common ancestry for ductal and small cell carcinoma. Case 2 showed 13q loss (involving RB1) in both adenocarcinoma and small cell carcinoma regions, and 3p gain, 4p loss, and 17p loss (involving TP53) in the latter. By using highly curated samples, we demonstrate for the first time that small-cell neuroendocrine and ductal prostatic carcinoma can have a common ancestry. We highlight whole genome doubling in a patient with prostate cancer relapse, reinforcing its poor prognostic nature.

Indexed as

Carcinoma, Acinar CellCarcinoma, DuctalCarcinoma, Small CellLung NeoplasmsProstatic NeoplasmsSmall Cell Lung CarcinomaAndrogen AntagonistsEvolution, MolecularHumansMalePhylogenyAndrogen Antagonistsgenomicsneuroendocrineprostate cancersmall celltumor evolutionwhole genome duplication

Identifiers

PMID37628903
PMCPMC10454593
OpenAlexW4385805852

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.